Vor Biopharma (VOR) Stock
Small biotech company developing treatments for blood cancers. Here's the price, business snapshot, and what's worth knowing about Vor Biopharma in October 2026.
VOR BioPharma (VOR) is a clinical-stage biotechnology company focused on developing novel therapies for haematologic malignancies and related conditions. The business is small by market-cap standards (about $190m) and is driven primarily by clinical programmes, trial milestones and partnership or funding announcements. For investors that follow early-stage biotech, the attraction lies in potential upside from positive clinical data, but the company also carries considerable binary risk: trial results, regulatory decisions and financing needs can move the share price sharply. Financials for small biotech can be volatile and may require periodic capital raises, which can dilute existing holders. This summary is educational only and not personalised financial advice; investors should assess suitability against their risk tolerance, do their own diligence and consider seeking regulated advice before acting.
Vor Biopharma (VOR) Stock Forecast
Analyst price target, next 12 months
$25.81
+41.4% vs today's $18.26
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Vor Biopharma have a consensus 12-month target of $25.81, above the current price of $18.26.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 26 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying VOR Biopharma's stock with a target price of $25.81, indicating strong growth potential.
Financial Health
VOR Biopharma is producing a strong cash flow, indicating good financial strength and operational efficiency.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical-stage focus
The company’s value is tied to trial progress and data readouts, which can create meaningful upside or downside depending on outcomes.
Catalysts to watch
Upcoming trial milestones, regulatory news and partnerships are potential share-price drivers, though results can be binary and unpredictable.
Finance & risks
As a small-cap biotech, VOR may need future fundraising that could dilute holdings; investors should weigh this alongside clinical risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
